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Abstract
Background: Kasabach-Merritt phenomenon (KMP) is characterized by a vascular tumor with profound
thrombocytopenia and consumptive coagulopathy that may presents significant challenges for anesthesiologist.
Case presentation: An 87-year-old man presented with kaposiform hemangioendothelioma involving the right leg
in critical condition due to massive bleeding. Hematology investigations indicated the presence of KMP. Association
of this type of tumor with KMP in adults has never been reported.
Conclusion: The present case report lays an emphasis on the potential difficulties during anesthetic management
of this rare condition.
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Background
Kasabach-Merritt phenomenon (KMP) is characterized
by giant hemangiomas, severe thrombocytopenia and
consumptive coagulopathy [1] that may cause life-
threatening complications and require aggressive treat-
ment. The anesthetic management of patients with this
trouble is challenging and rarely reported [2–4].
We report the anesthetic considerations in what we
believe to be the first report of adult-onset KHE associ-
ated with KMP.
Case presentation
An 87-year-old male, weighing 50 kg, presented at
emergency department in shock with cool clammy
extremities, palor, blood pressure (BP) of 85/35 mmHg
and tachycardia with heart rate (HR) of 130.
The past medical history was consistent of hyperten-
sion, diabetes mellitus and transurethral resection of
prostate under spinal anesthesia. He was on treatment
with amlodipine, metformine and dietary restriction.
Twelve months ago, he was diagnosed with KHE involv-
ing the right leg. A complete excision was performed on
the mass and a skin graft was applied from the homolat-
eral thigh. The surgical team successfully followed up
the patient for 9 months without recidivism. There were
no history of thrombocytopenia or other bleeding diath-
esis. The patient had not previously undergone any
chemotherapeutic agent known to cause cardiotoxicity.
On further examination, the patient was afebrile, alert
with oxygen saturation of 97 % and respiratory rate of 22.
The cardiopulmonary auscultation was normal. The abdo-
men was soft and free from tenderness on pressure. It was
noted the presence of multiple nodules developed in the
previous surgical site (Figs. 1 and 2). The tumor mass was
painless, immobile and sizing 12 × 6 × 5 cm. The overlying
skin was deep red-purple and bleeding spontaneously with
ecchymosis over and around the tumor.
Laboratory results demonstrated platelet count 24.000/
mm3, normocytic normochromic anemia with hemoglobin
6.3 g/dl, hematocrit 26 %, ASAT 20 IU/L, ALAT 23 IU/L,
ALP 70 IU/L, GGT 49 IU/L. Renal function, electrolytes
and ABG were normal. The coagulation tests were: pro-
thrombin time of 12.9 s (11 to 13.5 s), plasma fibrinogen
concentration of 2.70 g/l ((normal 1.50–3.87 g/L)), and
moderate increase in D-dimer 1.2 μg/mL (<0.5 μg/mL).
Laboratory workup revealed no evidence of hemolysis:
Bilirubin 0.8 mg/dl (normal 0,3 et 1,9 mg/dL), LDH
232 IU/L (normal 190–390 IU/L). No evidence of anti-
immune process was detected to account for destruction
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of these platelets as direct coombs test was negative.
The results of the initial septic screen were unremark-
able: C reactive protein of 7 mg/L, White cells count of
4.1 × 109/L and neutrophils of 3.2 × 109/L. Procalcitonin
was 0.1 ng/mL (<0.5 ng/mL). Blood and urine cultures at
the time of admission demonstrated no bacterial growth.
Heart failure secondary to massive arteriovenous shunt
across the lesion was excluded by a normal transthoracic
electrocardiography. The chest X-ray demonstrated mul-
tiple calcific densities throughout both lungs consistent
with calcified haemangiomas and already present in
previous radiographies.
Bleeding was not controlled despite compression dressing
over the lesion and the transfusion of packed RBCs (04
units) and platelet concentrates (10 units). Methylpredniso-
lone was injected intravenously (5 mg/kg) but no further
improvement in platelets or hemoglobin was observed. The
case has been discussed in a multidisciplinary setting in-
cluding hematologist, plastic surgeon and anesthesiologist.
In the absence of other alternatives, it was decided to carry
out another surgery in order to perform an amputation of
the right leg.
Pre-anesthetic evaluation did not reveal any abnor-
mal findings; particularly we excluded any associated
hemangioma involving the upper airway.
On arrival in our operating room (<3 h from admis-
sion), he had BP of 80/40 mmHg with HR of 125. 3-lead
ECG and pulse oximetry were monitored. A 16-Gauge
peripheral intravenous line was placed in his right
forearm and kept open with isotonic saline solution
(2000 ml). A radial arterial line was placed for continu-
ous monitoring of arterial blood pressure and for ABG
analysis and serum electrolytes during operation. A
double lumen catheter was inserted into the right
internal jugular vein under ultrasound guidance and was
used as an infusion route for noradrenalin. A rate of
1 μg/kg/min was necessary to reach and maintain a
mean arterial blood pressure above 65 mmHg.
After stabilizing the patient and adequate pre-oxygenation
of 5 min, general anesthesia was induced with rapid se-
quence induction using ketamine and succinylcholine. An
endotracheal tube size 7.0 mm was easily inserted. The
lungs were ventilated with a mixture of oxygen-air
(50–50 %) and anesthesia was maintained with 1 vol% of
sevoflurane. End expiratory CO2 and inspiratory O2
concentration were monitored. We requested the surgeon
to elevate the lower limb and rapidly apply a lower
extremity tourniquet in an attempt to minimize blood
loss. A transfemoral amputation was made (Fig. 3). As re-
sult of the sustained severe hemorrhage in this patient, he
required a massive transfusion of blood products which
starts earlier concomitant with the tourniquet manoeuver.
He received per-operatively a total of 07 units of RBCs, 10
units of platelets concentrate and 04 units of fresh frozen
Fig. 1 Anterior view of the tumor showing multiple nodules red-purple
and bleeding spontaneously with ecchymosis over and around
Fig. 2 Lateral view of the tumor
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plasma within 2 h. He was also given 4 g intravenous
calcium gluconate and 40 mg of furosemide. Pre-warming
of blood products and administered fluids and using of
patient warming device to prevent hypothermia was done.
After the above treatments, the vasopressor support was
withdrawn at the end of the surgery. The patient remained
hemodynamically stable and had adequate urine output.
Post operatively, he was shifted to the intensive care
unit (ICU) with mechanical ventilation support in stable
condition. Platelet count rapidly had increased to
66.000/mm3 and hemoglobin had improved to 10,3 g/dl.
The patient did not develop complications of massive
transfusion and no bleeding of incisional wound was
observed. Blood gas analysis showed pH 7.36, PCO
35 mmHg, PaO2 145 mmHg, bicarbonates 22.3 mmol/l.
Serum electrolytes were within normal range. Recovery
from anesthesia was smooth and quite well and he was
extubated in the same day. In the second post-operative
day, his report showed platelet count of 115.000/mm3
and hemoglobin of 9.9 g/dl. Anatomopathological exam-
ination of the surgical piece has revealed KHE (Fig. 4).
The patient was transferred to the department of plastic
surgery where the follow-up was uneventful. He was dis-
charged home after 1 month.
Discussion
KHE is a rare vascular proliferation of intermediate
malignancy and can arise during adulthood. The associ-
ation with thrombocytopenia or consumptive coagulopa-
thy is called Kasabach-Merritt phenomenon (KMP), also
known as Kasabach-Merritt syndrome [1]. Although the
pathogenesis of thrombocytopenia is not completely
understood, it is generally presumed that platelet-
trapping by abnormally proliferating endothelium within
the hemangioma and secondary activation of the coagu-
lation cascade are factors that lead to this condition [5].
In addition, the platelet half-life is drastically shortened
to between 1 and 24 h.
Croteau and colleagues reported that superficial KHE,
that are present in older aged people are associated with
decreased frequency of KMP [6]. Based on our know-
ledge, this particular case represents the first report of
adult-onset of KMP associated with KHE. The mortality
rate of KMP remains high, ranging from 12 to 24 % due
to hemorrhage, infection, invasion of vital structures,
and multiple organ failure [7, 8]. The high morbidity
and mortality rates observed in these patients necessitate
aggressive therapeutic intervention [9] of which surgical
excision of the tumor appears to be the most effective.
Other reported treatments include high-dose systemic
corticosteroids, vincristine, interferon, radiotherapy, and
propranolol. More recent and promising treatment is
sirolimus [10, 11]. Sirolimus has been described to decrease
tumor burden by suppressing mTOR (Mammalian target
of rapamycin) signaling pathway and causing cell apoptosis.
Because of the imminently life-threatening tumor, we
estimated that the time to respond to these medical therap-
ies is considered too long and consequently they were not
an option. In addition, the effectiveness of these treatments
has been inconsistent and currently, there are no known
treatment guidelines. Transarterial embolization is an
effective therapeutic option specially in case of unresectable
tumor due to its large size and infiltrating nature [12].
Unfortunately, this option was not available in our hospital
at the time of admission.
Fig. 3 Transfemoral amputation in our patient
Fig. 4 Histological features of the surgical piece. a Low power view of Kaposiform hemangioendothelioma shows Clustering of capillaries and
spindle cell nodules in larger nodular formations separated by fibrous septa. (hematoxylin and eosin stain, ×200). b Higher magnification showing
Crescent-like vascular slits and containing RBC’s. (hematoxylin and eosin stain,×400)
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Case reports regarding anesthesia in patients with
KMP are extremely rare [2–4]. These patients present
various challenges to anesthesiologist including: 1) un-
controllable hemorrhage, 2) enlarged lesion, 3) airway
obstruction (in cases where the lesion involves the head
and neck), 4) heart failure in case where the massive
arteriovenous shunt is across the lesion and 5) complica-
tions from massive blood transfusions.
The most common complication associated with the
anesthetic management of patients with KMP is se-
vere bleeding that can result from the disturbance of
blood coagulation. In addition to the severe, persistent
thrombocytopenia characteristic of KMP, patients often
manifest elevated D-dimer and low fibrinogen [7–13].
Severe anemia is also usually present [5].
A thorough hematologic examination that includes
complete blood count, coagulation screening and D-dimer
concentration is therefore critical in advance of the
surgery.
Platelet transfusion prior to surgery may exacerbate
KMP by enlarging the tumor and increasing the pain and
should therefore be avoided. Furthermore, de-granulating
platelets release proangiogenic molecules and may stimu-
late the tumor and increase the consumptive coagulopathy
[14]. When feasible, the use of tourniquet manoeuver may
decrease intraoperative blood loss. Use of antifibrinolytic
and antiplatelet agents has had mixed results [8–15].
Replacement of depleted clotting factors using fresh-
frozen plasma has been recommended in patients with
KMP before surgery [5]. Marked hypofibrinogenemia may
necessitate the administration of cryoprecipitate to correct
the underlying coagulopathy [16]. Recombinant factor VII
therapy was also reported in a child with KMP undergoing
major surgery [17].
Another anesthetic problem arises from the location
and size of the hemangioma. Kawahara and colleagues
[2] paid attention to this point. They reported a case of a
20-month-old girl with KMP who underwent the cryo-
surgical procedure to remove the angioma from her face.
Maintaining patient airways, ventilation and intubation
are major anesthetic concerns when the patient’s lesions
are located on the face because of challenges such as: 1)
fitting an anesthetic mask satisfactorily, 2) bleeding during
the endotracheal intubation and 3) airway obstruction
resulting from excitement or postural changes. The air-
passages should be examined carefully for any associated
hemangioma and the patient needs to be sufficiently pre-
medicated to avoid excitement before inducing anesthesia.
The use of a neuraxial anesthetic technique is not a
good choice in this case, because of bleeding tendencies
and the possibility of associated hemangiomas within
the soft tissue or spinal canal.
The use of modern volatile anesthetics reduce the
systemic vascular resistance and arterial blood pressure.
The intravenous anesthetics that affect the cardiovascu-
lar system exert a similar effect. Volatile anesthetics and
propofol induce redistribution of blood from the sys-
temic circulation to the venous malformation and can
lead to unexpected and disastrous effects in patients
with such vascular abnormalities. The combination of
both of these agents can have a synergistic effect [18]. In
our case, sevoflurane was used in a lower dose (1 vol %)
for inhalational maintenance. The use of ketamine seems
to be a beneficial alternative to propofol and volatile
agents [19].
Additional doses should be administered before and
during anesthesia if patients are already treated with ste-
roids to compensate for possible adrenal insufficiency.
Endovascular treatment is very challenging given the
complexity and individuality of the vasculature of the
tumor. The risks and benefits must be clearly explained
to the patient. General anesthesia is generally recom-
mended. Pretreatment with steroids is preferred to
control inflammatory response [20]. The procedure
should be performed as fast as possible to reduce the
catheterization time by practitioners with appropriate
training and support. Laboratory studies are performed
to test clotting parameters and renal function. Hydration
is recommended before the procedure to protect the
kidney from the effects of hemolysis [21]. Antibiotics are
usually given for 10 days after the procedure due to the
risk of infection. Antiemetics and analgesics may also be
administered. Postembolization syndrome can also occur
and is treated symptomatically [22].
Since massive bleeding may also occur, one should an-
ticipate the onset of hypotension and shock. It is reason-
able to invasively monitor these patients. A combination
of measures, including: 1) control of surgical bleeding,
2) supportive treatment with rapid fluid resuscitation, 3)
massive transfusion of blood products and administra-
tion of intravenous vasoactive agents for maintaining
tissue perfusion and 4) oxygenation are strongly recom-
mended in patients with severe bleeding. Massive
arteriovenous shunt across the lesion can precipitate
high output congestive heart failure and the scenario can
become more challenging. The anesthesiologist must be
aware for signs of heart failure.
Patients with KMP are likely to require massive blood
transfusions as illustrated in our case. This condition
can be associated with many complications, such as
acidosis, hypothermia, dilutional coagulopathy, electrolyte
abnormalities, citrate toxicity, and transfusion related
acute lung injury (TRALI). None of these complications
was observed in our case. Particular attention must be
paid to the prevention of secondary coagulopathy due to
hypothermia and acidosis. In our case, the patient was
prevented from hypothermia by pre-warming all adminis-
tered fluids and blood products as well as using patient
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warming devices, and increasing the operating room
temperature. The ABG analysis was repeated during the
procedure and did not show evidence of acidosis.
In the post‑operative period, patients should be trans-
ferred to the ICU with mechanical ventilator support and
the extubation must be guided by repeated monitoring of
ABG and hematological tests. In the case described here,
several different attempts to control the coagulopathy,
bleeding and anemia were fruitless and there was no other
option than to resection the hemangioma by amputation
of the limb as a final option to save the patient. Removal
of the hemangioma associated with prompt correction of
the patient’s physiologic disturbances leads to a rapid
recovery of the hematological profile.
Conclusion
KMP is a life-threatening condition requiring prompt
and effective treatment. The anesthesiologist should be
aware of the importance of some key considerations in
the anesthetic management of this rare situation and
anticipate complications that can lead to severe hemor-
rhaging, enlarged lesions, airway obstruction, massive
transfusion and heart failure.
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